Free Trial
NASDAQ:ARCT

Arcturus Therapeutics (ARCT) Stock Price, News & Analysis

Arcturus Therapeutics logo
$16.51 +1.03 (+6.65%)
(As of 05:26 PM ET)

About Arcturus Therapeutics Stock (NASDAQ:ARCT)

Key Stats

Today's Range
$15.13
$16.83
50-Day Range
$14.82
$21.15
52-Week Range
$14.30
$45.00
Volume
440,575 shs
Average Volume
467,865 shs
Market Capitalization
$447.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$66.75
Consensus Rating
Buy

Company Overview

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Arcturus Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
52nd Percentile Overall Score

ARCT MarketRank™: 

Arcturus Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 531st out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arcturus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Arcturus Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Arcturus Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Arcturus Therapeutics are expected to grow in the coming year, from ($2.31) to ($0.17) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arcturus Therapeutics is -7.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arcturus Therapeutics is -7.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Arcturus Therapeutics has a P/B Ratio of 1.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    17.78% of the float of Arcturus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Arcturus Therapeutics has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Arcturus Therapeutics has recently decreased by 2.46%, indicating that investor sentiment is improving.
  • Percentage of Shares Shorted

    17.78% of the float of Arcturus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Arcturus Therapeutics has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Arcturus Therapeutics has recently decreased by 2.46%, indicating that investor sentiment is improving.
  • News Sentiment

    Arcturus Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Arcturus Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    Only 3 people have searched for ARCT on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Arcturus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arcturus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $249,120.00 in company stock.

  • Percentage Held by Insiders

    15.30% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    94.54% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arcturus Therapeutics' insider trading history.
Receive ARCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARCT Stock News Headlines

Arcturus Therapeutics' (ARCT) Buy Rating Reiterated at HC Wainwright
Could This Tiny Device Help You Make an Extra $30k a Year?
I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.
See More Headlines

ARCT Stock Analysis - Frequently Asked Questions

Arcturus Therapeutics' stock was trading at $31.53 on January 1st, 2024. Since then, ARCT shares have decreased by 47.6% and is now trading at $16.51.
View the best growth stocks for 2024 here
.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) announced its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.70) by $0.44. The biotechnology company earned $41.67 million during the quarter, compared to analysts' expectations of $49.16 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative trailing twelve-month return on equity of 22.39%.

Top institutional investors of Arcturus Therapeutics include Sumitomo Mitsui Trust Group Inc. (8.45%), ARK Investment Management LLC (7.80%), State Street Corp (5.44%) and Geode Capital Management LLC (2.04%). Insiders that own company stock include Pad Chivukula, Magda Marquet and Keith C Kummerfeld.
View institutional ownership trends
.

Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arcturus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
11/07/2024
Today
12/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARCT
Fax
N/A
Employees
180
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$66.75
High Stock Price Target
$86.00
Low Stock Price Target
$48.00
Potential Upside/Downside
+304.3%
Consensus Rating
Buy
Rating Score (0-4)
3.14
Research Coverage
7 Analysts

Profitability

Net Income
$-29,730,000.00
Pretax Margin
-38.15%

Debt

Sales & Book Value

Annual Sales
$142.47 million
Book Value
$10.42 per share

Miscellaneous

Free Float
22,943,000
Market Cap
$447.21 million
Optionable
Optionable
Beta
2.62

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:ARCT) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners